GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ascendis Health Ltd (JSE:ASC) » Definitions » Gross Profit

Ascendis Health (JSE:ASC) Gross Profit : R605 Mil (TTM As of Jun. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Ascendis Health Gross Profit?

Ascendis Health's gross profit for the six months ended in Jun. 2023 was R293 Mil. Ascendis Health's gross profit for the trailing twelve months (TTM) ended in Jun. 2023 was R605 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Ascendis Health's gross profit for the six months ended in Jun. 2023 was R293 Mil. Ascendis Health's Revenue for the six months ended in Jun. 2023 was R758 Mil. Therefore, Ascendis Health's Gross Margin % for the quarter that ended in Jun. 2023 was 38.59%.

Ascendis Health had a gross margin of 38.59% for the quarter that ended in Jun. 2023 => Competition eroding margins

During the past 11 years, the highest Gross Margin % of Ascendis Health was 45.95%. The lowest was 37.98%. And the median was 41.21%.

Warning Sign:

Ascendis Health Ltd gross margin has been in long-term decline. The average rate of decline per year is -2.9%.


Ascendis Health Gross Profit Historical Data

The historical data trend for Ascendis Health's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Health Gross Profit Chart

Ascendis Health Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,601.89 846.16 693.31 637.73 604.53

Ascendis Health Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 542.18 341.13 296.61 311.90 292.64

Competitive Comparison of Ascendis Health's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Ascendis Health's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Health's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ascendis Health's Gross Profit distribution charts can be found below:

* The bar in red indicates where Ascendis Health's Gross Profit falls into.



Ascendis Health Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Ascendis Health's Gross Profit for the fiscal year that ended in Jun. 2023 is calculated as

Gross Profit (A: Jun. 2023 )=Revenue - Cost of Goods Sold
=1535.437 - 930.906
=605

Ascendis Health's Gross Profit for the quarter that ended in Jun. 2023 is calculated as

Gross Profit (Q: Jun. 2023 )=Revenue - Cost of Goods Sold
=758.223 - 465.587
=293

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was R605 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Ascendis Health's Gross Margin % for the quarter that ended in Jun. 2023 is calculated as

Gross Margin % (Q: Jun. 2023 )=Gross Profit (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=293 / 758.223
=38.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Ascendis Health  (JSE:ASC) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Ascendis Health had a gross margin of 38.59% for the quarter that ended in Jun. 2023 => Competition eroding margins


Ascendis Health Gross Profit Related Terms

Thank you for viewing the detailed overview of Ascendis Health's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascendis Health (JSE:ASC) Business Description

Traded in Other Exchanges
N/A
Address
1 Carey Street, Wynberg, Sandton, GT, ZAF, 2090
Ascendis Health is a drug manufacturer that produces and distributes health products for the human, animal, and plant markets. It has a portfolio of brands and products and owns recognized trademarks in the pharmaceutical and consumer health markets. Ascendis Health has five operating segments: consumer health, pharma, medical, animal health, and biosciences. The pharma division is the contributor to revenue and is further divided into Pharma Africa, Remedica, and Farmalider. Pharma includes generic manufacturing and distribution and over-the-counter medicine manufacturing and distribution. The company's revenue is split between South Africa and Europe and is diversified across currencies, markets, sales channels, and customer groups.